Clinical trials at doses up to 40mg daily for 12 weeks have reported no serious adverse effects (Brendler & Williamson, 2019, Phytomedicine )
Most patients describe a feeling of fullness and, therefore, they tend not to eat as much or have no appetite when on these medications
Patients may only receive retatrutide through: Approved clinical trials registered with the MHRA and listed on the ISRCTN or ClinicalTrials.gov registries The MHRA Early Access to Medicines Scheme (EAMS) or compassionate use programmes, which allow access to promising unlicensed medicines for patients with serious conditions where no adequate alternative exists however, no such route is currently in place for retatrutide , and patients should not assume access is available outside of a formal trial It is strongly advised that patients do not attempt to source retatrutide through unregulated online pharmacies or grey-market suppliers
it is the central component that regulates the stress response by stimulating the release of glucocorticoids from the adrenal cortex (Mulak, 2021)
Terkelsen MH, Klaestrup IH, Hvingelby V, Lauritsen J, Pavese N, Romero-Ramos M
It triggers all of them simultaneously
